Research & Development Market Research Reports & Industry Analysis
New product design and development is essential for the survival and growth of many companies, as markets and consumers’ tastes are fickle and the competition can be fierce. In order to stay relevant in a fast changing marketplace, firms have to constantly revise and expand their range of product offerings. Therefore, research and development is of great economic importance as companies fight to maintain their market share, though it may mean forgoing current profits in favor of potential future performance and returns.
Research and development is most often associated with the technology industry, as well as with science and in particular with healthcare and the development of new pharmaceuticals, diagnostics or medical devices that are safe and effective. For instance, drug makers must constantly search for the next big blockbuster drug, since the products they currently have on the market will eventually lose their patent protection and be vulnerable to generic competition. So they spend huge amounts of money on R&D because without a promising drug pipeline their revenue stream will ultimately dry up.
Research & Development Industry Research & Market Reports
-
Global Thymus Cancer Market - 2023-2030
... expected to exhibit a CAGR of 5.5% during the forecast period (2024-2031). The key players are adopting strategies such as partnerships, mergers, acquisitions, novel product launches and enhanced focus on R&D and regional expansion to ... Read More
-
Global Eosinophilic Esophagitis (EoE) Treatment Market - 2024 - 2031
... large numbers of white blood cells called eosinophils are present in the esophagus. It causes an inflammation of the esophagus caused by an overabundance of certain white blood cells. Food allergies are thought to be ... Read More
-
2025 Engineering and Life Sciences Research and Development Global Market Size & Growth Report with Updated Analysis & Forecasts
... 2013 through 2024, with forecasts for 2025 and 2029. The historical data utilizes in-depth survey results from companies in the Engineering and Life Sciences Research and Development industry combined with country and regional economic, firmographic, ... Read More
-
Global Legal Cannabis Market 2025-2029
... provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current market scenario, the latest ... Read More
-
Brand Name Pharmaceutical Manufacturing in the US - Industry Market Research Report
... Given increasing price scrutiny, competition from generics, intensifying market competition among brand-name producers and rising research and development expenses, many manufacturers have shifted their strategic focus to more lucrative therapy areas, such as rare diseases ... Read More
-
mRNA Platform
... CAGR of -2.7% over the analysis period 2024-2030. Covid-19 Vaccine Indication, one of the segments analyzed in the report, is expected to record a -6.3% CAGR and reach US$102.1 Billion by the end of the ... Read More
-
Cannabis Beverages
... CAGR of 16.3% over the analysis period 2024-2030. Non-Alcoholic Beverage, one of the segments analyzed in the report, is expected to record a 16.8% CAGR and reach US$2.1 Billion by the end of the analysis ... Read More
-
Contract Research Organization Services (CROs)
... Billion by 2030, growing at a CAGR of 10.6% over the analysis period 2024-2030. Clinical Research Services, one of the segments analyzed in the report, is expected to record a 11.4% CAGR and reach US$76.7 ... Read More
-
Drug Discovery Technologies
... at a CAGR of 8.7% over the analysis period 2024-2030. Small Molecule Drugs, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach US$92.7 Billion by the end ... Read More
-
Immunotherapy Drugs
... CAGR of 9.6% over the analysis period 2024-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 9.7% CAGR and reach US$254.4 Billion by the end of the analysis ... Read More
-
Non-alcoholic Steatohepatitis (NASH)
... at a CAGR of 55.7% over the analysis period 2024-2030. Vitamin E & Pioglitazone Drugs, one of the segments analyzed in the report, is expected to record a 45.3% CAGR and reach US$59.7 Billion by ... Read More
-
Carglumic Acid
... CAGR of 5.3% over the analysis period 2024-2030. Orally Disintegrating Tablets Delivery, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$105.6 Million by the end of ... Read More
-
Hereditary Angioedema
... CAGR of 7.7% over the analysis period 2024-2030. C1 Esterase Inhibitors, one of the segments analyzed in the report, is expected to record a 8.2% CAGR and reach US$2.5 Billion by the end of the ... Read More
-
In Vivo Contract Research Organization (CRO)
... reach US$8.0 Billion by 2030, growing at a CAGR of 6.9% over the analysis period 2024-2030. Smalll Molecules Modality, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and ... Read More
-
Marijuana Drying and Curing Equipment
... Million by 2030, growing at a CAGR of 9.5% over the analysis period 2024-2030. The U.S. Market is Estimated at US$55.2 Million While China is Forecast to Grow at 8.7% CAGR The Marijuana Drying and ... Read More
-
Preclinical Contract Research Organizations
... 2030, growing at a CAGR of 7.0% over the analysis period 2024-2030. Toxicology Testing Service, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$3.2 Billion by ... Read More
-
CBD Nutraceuticals
... CAGR of 18.1% over the analysis period 2024-2030. CBD Tinctures, one of the segments analyzed in the report, is expected to record a 16.2% CAGR and reach US$11.9 Billion by the end of the analysis ... Read More
-
Cancer Immunotherapy
... CAGR of 13.7% over the analysis period 2024-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 14.5% CAGR and reach US$266.2 Billion by the end of the analysis ... Read More
-
Cannabis Edibles
... CAGR of 22.0% over the analysis period 2024-2030. Solid Cannabis Edibles, one of the segments analyzed in the report, is expected to record a 22.2% CAGR and reach US$38.2 Billion by the end of the ... Read More
-
Colorectal Cancer Therapeutics
... at a CAGR of 6.5% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$14.9 Billion by the end of ... Read More
-
Male Hypogonadism
... CAGR of 5.1% over the analysis period 2024-2030. Testosterone Replacement Therapy, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$3.5 Billion by the end of the ... Read More
-
Medical Marijuana
... CAGR of 14.4% over the analysis period 2024-2030. Extract Form, one of the segments analyzed in the report, is expected to record a 14.7% CAGR and reach US$60.5 Billion by the end of the analysis ... Read More
-
CBD Gummies
... CAGR of 28.8% over the analysis period 2024-2030. Low Concentration CBD Gummies, one of the segments analyzed in the report, is expected to record a 28.2% CAGR and reach US$32.4 Billion by the end of ... Read More
-
Cannabis Extract
... CAGR of 15.6% over the analysis period 2024-2030. Cannabis Oils, one of the segments analyzed in the report, is expected to record a 16.2% CAGR and reach US$34.1 Billion by the end of the analysis ... Read More
-
Cannabidiol
... 14.5% over the analysis period 2024-2030. Hemp-sourced Cannabidiol, one of the segments analyzed in the report, is expected to record a 15.7% CAGR and reach US$14.3 Billion by the end of the analysis period. Growth ... Read More
Research Assistance
